Related Experiment Video

Updated: May 17, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy

Shu-Fu Lin1, Yu-Yao Huang, Jen-Der Lin

  • 1Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, Republic of China. mmg@cgmh.org.tw

Plos One
|October 19, 2012
PubMed
Abstract

Insights

The dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235) effectively inhibits thyroid cancer cell proliferation. BEZ235 shows synergistic effects with paclitaxel in anaplastic thyroid cancer, supporting further clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Thyroid cancer presents a significant therapeutic challenge.
  • Targeting the PI3K/mTOR pathway is a promising strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of NVP-BEZ235 (BEZ235) as a single agent and in combination with chemotherapy for thyroid cancer.
  • To investigate the molecular mechanisms underlying BEZ235's action in thyroid cancer.

Main Methods:

  • Cytotoxicity assays (LDH) were performed on eight thyroid cancer cell lines.
  • Western blot and flow cytometry analyzed cell cycle, apoptosis, and signaling pathways.
  • In vivo efficacy was assessed using anaplastic thyroid cancer (ATC) xenograft models.

Main Results:

  • BEZ235 inhibited proliferation across all tested thyroid cancer types, with ATC showing highest sensitivity.
  • BEZ235 inactivated mTORC1 signaling, induced G0/G1 cell cycle arrest, and apoptosis in sensitive cell lines.
  • Combination therapy with paclitaxel demonstrated synergistic effects against ATC in vitro, and BEZ235 inhibited tumor growth in vivo without toxicity.

Conclusions:

  • BEZ235 demonstrates significant potential as a single agent for thyroid cancer.
  • Combination therapy with paclitaxel shows promise for treating anaplastic thyroid cancer.
  • These findings warrant further clinical investigation of BEZ235 for advanced thyroid cancer.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.